Hellman and Friedman seeks over nine billion dollars in early talks to sell medical device manufacturer Cordis
Hellman and Friedman is in early discussions to sell Cordis for over nine billion dollars. Multiple medical device companies are evaluating potential bids.
Insights:
Private equity firm Hellman and Friedman is in early-stage discussions for a potential sale of its cardiovascular medical device manufacturer Cordis. The firm is seeking a valuation target exceeding $9 billion for the company. Approximately half a dozen publicly traded medical device companies are currently evaluating potential bids for the manufacturer as interest in the cardiovascular market remains high within the US 
US.
US.The potential transaction represents a significant liquidity event for Hellman and Friedman. The private equity firm acquired Cordis from Cardinal Health Inc. in 2021 for a price of approximately $1 billion. Before that acquisition, Cardinal Health Inc.had held the company for several years after purchasing it from its previous owner.
